Lerodalcibep is under clinical development by LIB Therapeutics and currently in Phase III for Heterozygous familial hypercholesterolemia (heFH). According to GlobalData, Phase III drugs for Heterozygous familial hypercholesterolemia (heFH) have a 73% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Lerodalcibep’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Lerodalcibep overview
Lerodalcibep is under development for the treatment of hypercholesterolemia, homozygous familial hypercholesterolemia and heterozygous familial hypercholesterolemia (heFH). The drug candidate is administered through subcutaneous route. It acts by targeting PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9). The drug candidate is a Chinese hamster ovary-cell line-derived recombinant fusion protein consisting of a PCSK9-binding domain and human serum albumin (HSA).
LIB Therapeutics overview
LIB Therapeutics, is a Biotechnology company. The company researches and develops subcutaneous and oral PCSK9 inhibitors to the patients suffering with cardiovascular disease. The company is headquartered in Cincinnati, Ohio, the US.
For a complete picture of Lerodalcibep’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
